Loading...
XNASMLTX
Market cap3.32bUSD
Dec 24, Last price  
52.67USD
1D
1.02%
1Q
3.66%
IPO
400.67%
Name

MoonLake Immunotherapeutics

Chart & Performance

D1W1MN
XNAS:MLTX chart
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
Net income
-36m
L-44.18%
-90,838-53,643,615-64,506,051-36,007,260
CFO
-43m
L-23.47%
-316,692-35,175,194-55,893,900-42,778,167
Earnings
Feb 26, 2025

Profile

Helix Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses or entities. The company was founded in 2020 and is based in Boston, Massachusetts.
IPO date
Oct 20, 2020
Employees
20
Domiciled in
CH
Incorporated in
KY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFY
2023‑122022‑122021‑122020‑12
Income
Revenues
Cost of revenue
54,136
65,074
75,213
Unusual Expense (Income)
NOPBT
(54,136)
(65,074)
(75,213)
NOPBT Margin
Operating Taxes
94
36
5
Tax Rate
NOPAT
(54,231)
(65,110)
(75,217)
Net income
(36,007)
-44.18%
(64,506)
20.25%
(53,644)
58,954.16%
Dividends
Dividend yield
Proceeds from repurchase of equity
482,454
4
28,263
BB yield
-16.26%
0.00%
-36.45%
Debt
Debt current
1,306
154
15,000
Long-term debt
6,306
412
Deferred revenue
Other long-term liabilities
583
282
240
Net debt
(503,396)
(71,550)
(108,081)
Cash flow
Cash from operating activities
(42,778)
(55,894)
(35,175)
CAPEX
(285)
(16)
(51)
Cash from investing activities
(25,184)
(32,341)
(51)
Cash from financing activities
479,702
119,693
43,263
FCF
(57,848)
(65,396)
(75,047)
Balance
Cash
511,008
72,115
8,039
Long term investments
115,043
Excess cash
511,008
72,115
123,081
Stockholders' equity
(96,478)
(60,426)
(53,701)
Invested Capital
614,359
129,647
57,232
ROIC
ROCE
EV
Common stock shares outstanding
49,123
29,361
7,841
Price
60.39
475.14%
10.50
6.17%
9.89
-13.02%
Market cap
2,966,510
862.23%
308,294
297.57%
77,545
-53.93%
EV
2,480,929
256,613
(30,464)
EBITDA
(54,123)
(65,061)
(75,208)
EV/EBITDA
0.41
Interest
592
Interest/NOPBT